priZm Therapeutics
  • Home
  • PriZmTX
  • About Us
  • MCT8 Deficiency (AHDS)
  • News
  • Careers
  • Contact
  • Clinical Study
  • SRW101
logo

Richard W. Pascoe

Slide Richard W. Pascoe Richard W. Pascoe was named to the PriZm Therapeutics board of directors in June of 2023. He was previously the Executive Chairman of Zevra Therapeutics, a rare disease company, from November of 2021to December of 2022 and Chief Executive Officer from January of 2023 to June of 2023. He was Chief Executive Officer of Histogen Inc. from January of 2019 to November of 2021. Mr. Pascoe was the Chief Executive Officer of Apricus Biosciences, Inc. from March 2013 until January 2019. Prior to Apricus, Mr. Pascoe was with Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics, Inc.) where he served as the Chief Executive Officer.

Prior to joining Somaxon in 2008, Mr. Pascoe held a series of senior management roles to include Chief Operating Officer at ARIAD Pharmaceuticals, Inc. (acquired by Takeda Inc.) and Senior Vice President of Neuroscience Division at King Pharmaceuticals, Inc. (acquired by Pfizer Inc.). Prior to King, Mr. Pascoe held commercial roles in the hospital pharmaceutical and medical device groups at Medco Research, Inc. (acquired by King), COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals Inc.), and B. Braun Interventional.

Mr. Pascoe is a member of the board of directors of Seelos Therapeutics, Inc. He is the past chairman of the board of directors of Biocom, California’s leading advocate for the life sciences industry, and a member of the board of directors of the Johnny Mac Soldiers Fund which serves the families of our nation’s fallen service members.


Mr. Pascoe served on active duty as a commissioned officer with the U.S. Army’s 24th Infantry Division with one combat tour in Iraq where he earned several awards and decorations including the Bronze Star Medal. He is a graduate of the United States Military Academy at West Point where he received a B.S. degree in Leadership. Mr. Pascoe was appointed as the Civilian Aide to the Secretary of the Army for Southern California in 2017, where he served as a liaison between the Secretary of the Army and the local community until November 2021.

On June 22, 2023   /    

About This Sidebar

  • To edit this sidebar, go to admin backend's Appearance -> Widgets and place widgets into the BlogSidebar Widget Area

A late-stage clinical biotech company developing therapies for ultra-rare pediatric orphan diseases

 

 

 

 

 

© 2023 PriZm, LLC
Back to Top